Skip to main content
Erschienen in: Diabetologia 7/2006

01.07.2006 | Article

Plasma apolipoprotein A5 and triglycerides in type 2 diabetes

verfasst von: G. M. Dallinga-Thie, A. van Tol, H. Hattori, L. C. van Vark-van der Zee, H. Jansen, E. J. G. Sijbrands, on behalf of the DALI study group

Erschienen in: Diabetologia | Ausgabe 7/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Variation in the human apolipoprotein (APO) A5 gene (APOA5) is associated with elevated plasma triglycerides. However, data on the exact role of plasma concentrations of APOA5 in human triglyceride homeostasis are lacking. In the present study, we estimated plasma APOA5 levels in patients with type 2 diabetes at baseline and during atorvastatin treatment, a lipid-lowering treatment that results in a reduction in plasma triglycerides and APOC3.

Subjects, materials and methods

Plasma APOA5 concentration was measured by ELISA in 215 subjects with type 2 diabetes, who were taken from the Diabetes Atorvastatin Lipid-lowering Intervention (DALI) study, a 30-week randomised, double-blind, placebo-controlled study, and given atorvastatin 10 mg or 80 mg daily.

Results

At baseline, average plasma APOA5 concentration was 25.7±15.6 μg/100 ml. Plasma APOA5 (R s=0.40), APOC3 (R s=0.72) and APOE (R s=0.45) were positively correlated with plasma triglyceride levels (all p<0.001). In multiple linear regression analysis, adjusted for age and sex, the variation in plasma triglycerides was explained mostly by APOC3 (52%) and only to a small extent by APOA5 (6%) and APOE (1%). Atorvastatin treatment decreased plasma triglycerides, APOA5, APOC3 and APOE (all p<0.0001). After treatment, APOC3 remained the major determinant of plasma triglyceride levels (59%), while the contributions of APOA5 and APOE were insignificant (2 and 3%).

Conclusions/interpretation

Our findings reveal a positive association between plasma APOA5 and triglycerides in patients with type 2 diabetes. Treatment with atorvastatin decreased plasma APOA5, APOC3, APOE and triglycerides. In contrast to APOC3, APOA5 is not a major determinant of triglyceride metabolism in these patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Austin MA, McKnight B, Edwards KL et al (2000) Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 101:2777–2782PubMed Austin MA, McKnight B, Edwards KL et al (2000) Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 101:2777–2782PubMed
2.
Zurück zum Zitat Hokanson JE, Austin MA (1996) Plasma triglyceride is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol: a meta analysis of population based prospective studies. J Cardiovasc Res 3:213–219CrossRef Hokanson JE, Austin MA (1996) Plasma triglyceride is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol: a meta analysis of population based prospective studies. J Cardiovasc Res 3:213–219CrossRef
3.
Zurück zum Zitat Groenendijk M, Cantor RM, De Bruin TWA, Dallinga-Thie GM (2001) The apoAI-CIII-AIV gene cluster. Atherosclerosis 157:1–11PubMedCrossRef Groenendijk M, Cantor RM, De Bruin TWA, Dallinga-Thie GM (2001) The apoAI-CIII-AIV gene cluster. Atherosclerosis 157:1–11PubMedCrossRef
4.
Zurück zum Zitat Brewer HB Jr, Rader DJ (1991) HDL: structure, function and metabolism. Prog Lipid Res 30:139–144PubMedCrossRef Brewer HB Jr, Rader DJ (1991) HDL: structure, function and metabolism. Prog Lipid Res 30:139–144PubMedCrossRef
5.
Zurück zum Zitat Jong MC, Hofker MH, Havekes LM (1999) Role of ApoCs in lipoprotein metabolism-functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19:472–484PubMed Jong MC, Hofker MH, Havekes LM (1999) Role of ApoCs in lipoprotein metabolism-functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19:472–484PubMed
6.
Zurück zum Zitat Fujimoto K, Cardelli JA, Tso P (1992) Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation. Am J Physiol 262:G1002–G1006PubMed Fujimoto K, Cardelli JA, Tso P (1992) Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation. Am J Physiol 262:G1002–G1006PubMed
7.
Zurück zum Zitat Pennacchio LA, Olivier M, Hubacek JA et al (2001) An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294:169–173PubMedCrossRef Pennacchio LA, Olivier M, Hubacek JA et al (2001) An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294:169–173PubMedCrossRef
8.
Zurück zum Zitat Pennacchio LA, Rubin EM (2003) Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol 23:529–534PubMedCrossRef Pennacchio LA, Rubin EM (2003) Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol 23:529–534PubMedCrossRef
9.
Zurück zum Zitat Grosskopf I, Baroukh N, Lee SJ et al (2005) Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol 25:2573–2579PubMedCrossRef Grosskopf I, Baroukh N, Lee SJ et al (2005) Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol 25:2573–2579PubMedCrossRef
10.
Zurück zum Zitat Fruchart-Najib J, Bauge E, Niculescu LS et al (2004) Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 319:397–404PubMedCrossRef Fruchart-Najib J, Bauge E, Niculescu LS et al (2004) Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 319:397–404PubMedCrossRef
11.
Zurück zum Zitat Vliet HNvd, Schaap FG, Levels JH et al (2002) Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun 295:1156–1159PubMedCrossRef Vliet HNvd, Schaap FG, Levels JH et al (2002) Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun 295:1156–1159PubMedCrossRef
12.
Zurück zum Zitat Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC (2002) Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 11:3031–3038PubMedCrossRef Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC (2002) Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 11:3031–3038PubMedCrossRef
13.
Zurück zum Zitat Talmud PJ, Hawe E, Martin S et al (2002) Relative contribution of variation within the ApoC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 11:3039–3046PubMedCrossRef Talmud PJ, Hawe E, Martin S et al (2002) Relative contribution of variation within the ApoC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 11:3039–3046PubMedCrossRef
14.
Zurück zum Zitat Berk-Planken II, Hoogerbrugge N, Jansen H et al (2001) The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia—The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24:1335–1341CrossRef Berk-Planken II, Hoogerbrugge N, Jansen H et al (2001) The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia—The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24:1335–1341CrossRef
15.
Zurück zum Zitat Dallinga-Thie GM, Berk-Planken II, Bootsma AH, Jansen H (2004) Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes Care 27:1358–1364PubMedCrossRef Dallinga-Thie GM, Berk-Planken II, Bootsma AH, Jansen H (2004) Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes Care 27:1358–1364PubMedCrossRef
16.
Zurück zum Zitat No authors listed (2000) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 23:S4–S19 No authors listed (2000) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 23:S4–S19
17.
Zurück zum Zitat Ishihara M, Kujiraoka T, Iwasaki T et al (2005) A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res 46:2015–2022PubMedCrossRef Ishihara M, Kujiraoka T, Iwasaki T et al (2005) A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res 46:2015–2022PubMedCrossRef
18.
Zurück zum Zitat Dallinga-Thie GM, Bu XD, Trip MV, Rotter JI, Lusis AJ, De Bruin TWA (1996) Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 37:136–147PubMed Dallinga-Thie GM, Bu XD, Trip MV, Rotter JI, Lusis AJ, De Bruin TWA (1996) Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 37:136–147PubMed
19.
Zurück zum Zitat O’Brien PJ, Alborn WE, Sloan JH et al (2005) The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 51:351–359PubMedCrossRef O’Brien PJ, Alborn WE, Sloan JH et al (2005) The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 51:351–359PubMedCrossRef
20.
Zurück zum Zitat Olofsson SO (2005) ApoA-V: the regulation of a regulator of plasma triglycerides. Arterioscler Thromb Vasc Biol 25:1097–1099PubMedCrossRef Olofsson SO (2005) ApoA-V: the regulation of a regulator of plasma triglycerides. Arterioscler Thromb Vasc Biol 25:1097–1099PubMedCrossRef
21.
Zurück zum Zitat Merkel M, Loeffler B, Kluger M et al (2005) Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 280:21553–21560PubMedCrossRef Merkel M, Loeffler B, Kluger M et al (2005) Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 280:21553–21560PubMedCrossRef
22.
Zurück zum Zitat Pruneta-Deloche V, Ponsin G, Groisne L, Fruchart-Najib J, Lagarde M, Moulin P (2005) Postprandial increase of plasma apoAV concentrations in type 2 diabetic patients. Atherosclerosis 181:403–405PubMedCrossRef Pruneta-Deloche V, Ponsin G, Groisne L, Fruchart-Najib J, Lagarde M, Moulin P (2005) Postprandial increase of plasma apoAV concentrations in type 2 diabetic patients. Atherosclerosis 181:403–405PubMedCrossRef
23.
Zurück zum Zitat Baroukh N, Bauge E, Akiyama J et al (2004) Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol 24:1297–1302PubMedCrossRef Baroukh N, Bauge E, Akiyama J et al (2004) Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol 24:1297–1302PubMedCrossRef
24.
Zurück zum Zitat Chan DC, Watts GF, Nguyen MN, Barrett H (2006) Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics. Arterioscler Thromb Vasc Biol 26:590–596PubMedCrossRef Chan DC, Watts GF, Nguyen MN, Barrett H (2006) Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics. Arterioscler Thromb Vasc Biol 26:590–596PubMedCrossRef
25.
Zurück zum Zitat Endo K, Yanagi H, Araki J, Hirano C, Yamakawa-Kobayashi K, Tomura S (2002) Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet 111:570–572PubMedCrossRef Endo K, Yanagi H, Araki J, Hirano C, Yamakawa-Kobayashi K, Tomura S (2002) Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet 111:570–572PubMedCrossRef
26.
Zurück zum Zitat Aouizerat BE, Kulkarni M, Heilbron D et al (2003) Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. J Lipid Res 44:1167–1173PubMedCrossRef Aouizerat BE, Kulkarni M, Heilbron D et al (2003) Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. J Lipid Res 44:1167–1173PubMedCrossRef
27.
Zurück zum Zitat Evans D, Buchwald A, Beil FU (2003) The single nucleotide polymorphism −1131T>C in the apolipoprotein A5 (ApoA5) gene is associated with elevated triglycerides in patients with hyperlipidemia. J Mol Med 81:645–654PubMedCrossRef Evans D, Buchwald A, Beil FU (2003) The single nucleotide polymorphism −1131T>C in the apolipoprotein A5 (ApoA5) gene is associated with elevated triglycerides in patients with hyperlipidemia. J Mol Med 81:645–654PubMedCrossRef
28.
Zurück zum Zitat Wright WT, Young IS, Nicholls DP, Patterson C, Lyttle K, Graham CA (2005) SNPs at the ApoA5 gene account for the strong association with hypertriglyceridaemia at the ApoA5/A4/C3/A1 locus on chromosome 11q23 in the Northern Irish population. Atherosclerosis 185:353–360PubMedCrossRef Wright WT, Young IS, Nicholls DP, Patterson C, Lyttle K, Graham CA (2005) SNPs at the ApoA5 gene account for the strong association with hypertriglyceridaemia at the ApoA5/A4/C3/A1 locus on chromosome 11q23 in the Northern Irish population. Atherosclerosis 185:353–360PubMedCrossRef
29.
Zurück zum Zitat Eichenbaum-Voline S, Olivier M, Jones EL et al (2004) Linkage and association between distinct variants of the ApoA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 24:167–174PubMedCrossRef Eichenbaum-Voline S, Olivier M, Jones EL et al (2004) Linkage and association between distinct variants of the ApoA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 24:167–174PubMedCrossRef
30.
Zurück zum Zitat Mar R, Pajukanta P, Allayee H et al (2004) Association of the Apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ Res 94:993–999PubMedCrossRef Mar R, Pajukanta P, Allayee H et al (2004) Association of the Apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ Res 94:993–999PubMedCrossRef
31.
Zurück zum Zitat Austin MA, Talmud PJ, Farin FM et al (2004) Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans. Biochim Biophys Acta 1688:1–9PubMed Austin MA, Talmud PJ, Farin FM et al (2004) Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans. Biochim Biophys Acta 1688:1–9PubMed
32.
Zurück zum Zitat Martin S, Nicaud V, Humphries SE, Talmud PJ (2003) Contribution of ApoA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta 1637:217–225PubMed Martin S, Nicaud V, Humphries SE, Talmud PJ (2003) Contribution of ApoA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta 1637:217–225PubMed
33.
Zurück zum Zitat Talmud PJ, Palmen J, Putt W, Lins L, Humphries SE (2005) Determination of the functionality of common ApoA5 polymorphisms. J Biol Chem 280:28215–28220PubMedCrossRef Talmud PJ, Palmen J, Putt W, Lins L, Humphries SE (2005) Determination of the functionality of common ApoA5 polymorphisms. J Biol Chem 280:28215–28220PubMedCrossRef
34.
Zurück zum Zitat Vu-Dac N, Gervois P, Jakel H et al (2003) Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 278:17982–17985PubMedCrossRef Vu-Dac N, Gervois P, Jakel H et al (2003) Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 278:17982–17985PubMedCrossRef
35.
Zurück zum Zitat Schoonjans K, Peinado-Onsurbe J, Fruchart JC, Tailleux A, Fiévet C, Auwerx J (1999) 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett 452:160–164PubMedCrossRef Schoonjans K, Peinado-Onsurbe J, Fruchart JC, Tailleux A, Fiévet C, Auwerx J (1999) 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett 452:160–164PubMedCrossRef
Metadaten
Titel
Plasma apolipoprotein A5 and triglycerides in type 2 diabetes
verfasst von
G. M. Dallinga-Thie
A. van Tol
H. Hattori
L. C. van Vark-van der Zee
H. Jansen
E. J. G. Sijbrands
on behalf of the DALI study group
Publikationsdatum
01.07.2006
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 7/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0261-0

Weitere Artikel der Ausgabe 7/2006

Diabetologia 7/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.